Published in Mol Cell Biol on March 09, 2009
Potential tumor suppressor NESG1 as an unfavorable prognosis factor in nasopharyngeal carcinoma. PLoS One (2011) 0.94
Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J Biol Chem (2010) 0.85
Grb2 monomer-dimer equilibrium determines normal versus oncogenic function. Nat Commun (2015) 0.76
Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy. Sci Rep (2016) 0.75
Co-occurring protein phosphorylation are functionally associated. PLoS Comput Biol (2017) 0.75
The bone morphogenetic protein receptor-1A pathway is required for lactogenic differentiation of mammary epithelial cells in vitro. In Vitro Cell Dev Biol Anim (2012) 0.75
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell (1992) 8.20
Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A (1993) 6.19
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer (2001) 5.96
Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev (1997) 5.57
Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature (1992) 5.47
Information networks in the mammary gland. Nat Rev Mol Cell Biol (2005) 3.57
Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev (1997) 3.12
Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development (1999) 2.89
Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. EMBO J (1988) 2.82
Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J (1997) 2.28
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol (2004) 1.78
Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene (2005) 1.76
Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. EMBO J (2001) 1.52
Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene (2003) 1.51
The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res (1999) 1.41
Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer (2006) 1.24
Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res (2006) 1.23
The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem (2001) 1.22
Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anticancer Drugs (2006) 1.11
Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. Mol Endocrinol (1995) 1.08
Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene (2006) 1.04
Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene (2006) 1.03
Dominant-negative mutants of the SH2/SH3 adapters Nck and Grb2 inhibit MAP kinase activation and mesoderm-specific gene induction by eFGF in Xenopus. Oncogene (1998) 0.99
Prolactin receptor regulates Stat5 tyrosine phosphorylation and nuclear translocation by two separate pathways. J Biol Chem (1998) 0.97
Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene (2000) 0.97
Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells. Mol Endocrinol (2004) 0.94
A single phosphotyrosine residue of the prolactin receptor is responsible for activation of gene transcription. Proc Natl Acad Sci U S A (1995) 0.93
Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis (2003) 0.90
Prolactin decreases epidermal growth factor receptor kinase activity via a phosphorylation-dependent mechanism. J Biol Chem (1998) 0.86
Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. J Endocrinol (2006) 0.86
Short-hairpin RNA-mediated stable silencing of Grb2 impairs cell growth and DNA synthesis. Biochem Biophys Res Commun (2007) 0.84
Prolactin and epidermal growth factor regulation of the proliferation, morphogenesis, and functional differentiation of normal rat mammary epithelial cells in three dimensional primary culture. J Cell Physiol (1995) 0.83
Potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics. Bioorg Med Chem Lett (2003) 0.80
The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2. Cell Signal (2003) 0.79
Prolactin inhibits EGF-induced DNA synthesis in mammary epithelium via early signaling mechanisms: possible involvement of protein kinase C. Exp Cell Res (1997) 0.78
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Role of HER2 in wound-induced breast carcinoma proliferation. Lancet (2003) 3.40
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood (2009) 2.31
Biologic and therapeutic role of HER2 in cancer. Oncogene (2003) 2.26
A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion. Breast Cancer Res (2012) 1.70
Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Res (2013) 1.64
Apoptosis induction by trastuzumab: possible role of the core biopsy intervention. J Clin Oncol (2005) 1.49
Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more? J Clin Oncol (2004) 1.46
Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol (2012) 1.45
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res (2007) 1.45
Phagocyte cell migration is mediated by phospholipases PLD1 and PLD2. Blood (2006) 1.44
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol (2006) 1.37
Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR. FASEB J (2007) 1.36
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat (2007) 1.31
Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res (2006) 1.23
Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression. Clin Cancer Res (2008) 1.23
Activin and TGFβ regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells. Cell Signal (2013) 1.22
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res (2011) 1.20
Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J Biol Chem (2002) 1.19
Activin/TGF-beta induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nat Cell Biol (2002) 1.19
SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor. J Biol Chem (2003) 1.12
Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer (2008) 1.12
The G protein-coupled receptor kinase-2 is a TGFbeta-inducible antagonist of TGFbeta signal transduction. EMBO J (2005) 1.09
A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling. Blood (2003) 1.08
Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors. Cell Signal (2007) 1.06
Inhibition of angiotensin convertin enzyme (ACE) activity by the anthocyanins delphinidin- and cyanidin-3-O-sambubiosides from Hibiscus sabdariffa. J Ethnopharmacol (2009) 1.06
An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res (2002) 1.05
Right-sided diaphragmatic rupture after blunt trauma. An unusual entity. World J Emerg Surg (2011) 1.05
Molecular crosstalk between p70S6k and MAPK cell signaling pathways. Biochem Biophys Res Commun (2002) 1.02
SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther (2010) 1.02
Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and Sp1. Cell Signal (2004) 1.02
Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Mod Pathol (2006) 1.01
HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res (2002) 1.00
Phosphatidic acid is a leukocyte chemoattractant that acts through S6 kinase signaling. J Biol Chem (2010) 1.00
HER2 as a target for breast cancer therapy. Expert Opin Biol Ther (2010) 0.99
IONP-PLL: a novel non-viral vector for efficient gene delivery. J Gene Med (2003) 0.98
A comprehensive model that explains the regulation of phospholipase D2 activity by phosphorylation-dephosphorylation. Mol Cell Biol (2010) 0.98
Evidence for two CRIB domains in phospholipase D2 (PLD2) that the enzyme uses to specifically bind to the small GTPase Rac2. J Biol Chem (2011) 0.98
Molecular and functional expression of cation-chloride cotransporters in dorsal root ganglion neurons during postnatal maturation. J Neurophysiol (2012) 0.98
Phospholipase D2 (PLD2) is a guanine nucleotide exchange factor (GEF) for the GTPase Rac2. Proc Natl Acad Sci U S A (2011) 0.98
The Grb2/PLD2 interaction is essential for lipase activity, intracellular localization and signaling in response to EGF. J Mol Biol (2007) 0.97
Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology (2011) 0.97
Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer (2007) 0.96
The molecular basis of phospholipase D2-induced chemotaxis: elucidation of differential pathways in macrophages and fibroblasts. Mol Cell Biol (2010) 0.96
FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc Natl Acad Sci U S A (2006) 0.95
IL-8-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3). FEBS Lett (2010) 0.95
The uncovering of a novel regulatory mechanism for PLD2: formation of a ternary complex with protein tyrosine phosphatase PTP1B and growth factor receptor-bound protein GRB2. Biochem Biophys Res Commun (2005) 0.94
Smad signaling antagonizes STAT5-mediated gene transcription and mammary epithelial cell differentiation. J Biol Chem (2007) 0.94
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem (2014) 0.94
The mechanism of cell membrane ruffling relies on a phospholipase D2 (PLD2), Grb2 and Rac2 association. Cell Signal (2011) 0.93
MicroRNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1), a new signaling route through which transforming growth factor-β Mediates the migration and actin dynamics of breast cancer cells. J Biol Chem (2013) 0.93
The dual effect of Rac2 on phospholipase D2 regulation that explains both the onset and termination of chemotaxis. Mol Cell Biol (2011) 0.93
A novel phospholipase D2-Grb2-WASp heterotrimer regulates leukocyte phagocytosis in a two-step mechanism. Mol Cell Biol (2011) 0.92
Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and Janus kinase 3 (JAK3). J Mol Biol (2011) 0.92
Activity and resistance of trastuzumab according to different clinical settings. Cancer Treat Rev (2011) 0.90
Understanding phospholipase D (PLD) using leukocytes: PLD involvement in cell adhesion and chemotaxis. J Leukoc Biol (2007) 0.90
Poly(L-lysine)-modified silica nanoparticles for the delivery of antisense oligonucleotides. Biotechnol Appl Biochem (2004) 0.90
An analysis on the combination expression of HPV L1 capsid protein and p16INK4a in cervical lesions. Diagn Cytopathol (2010) 0.90
Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Res Treat (2007) 0.89
TGFbeta-induced GRK2 expression attenuates AngII-regulated vascular smooth muscle cell proliferation and migration. Cell Signal (2009) 0.89
Identification of the catalytic site of phospholipase D2 (PLD2) newly described guanine nucleotide exchange factor activity. J Biol Chem (2012) 0.88
Serum deprivation confers the MDA-MB-231 breast cancer line with an EGFR/JAK3/PLD2 system that maximizes cancer cell invasion. J Mol Biol (2012) 0.88
Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res (2007) 0.88
Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. J Cell Physiol (2010) 0.87
Hexachlorobenzene triggers AhR translocation to the nucleus, c-Src activation and EGFR transactivation in rat liver. Toxicol Lett (2008) 0.87
Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. Cancer (2009) 0.87
Cytotoxic podophyllotoxin type-lignans from the steam bark of Bursera fagaroides var. fagaroides. Molecules (2012) 0.86
Chemical composition of hexane extract of Citrus aurantifolia and anti-Mycobacterium tuberculosis activity of some of its constituents. Molecules (2012) 0.86
Expression of the Slc12a1 gene in pancreatic β-cells: molecular characterization and in silico analysis. Cell Physiol Biochem (2012) 0.86
Mutation of Y179 on phospholipase D2 (PLD2) upregulates DNA synthesis in a PI3K-and Akt-dependent manner. Cell Signal (2007) 0.86
Mammalian target of rapamycin (mTOR) and S6 kinase down-regulate phospholipase D2 basal expression and function. J Biol Chem (2010) 0.85
Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. Nat Clin Pract Oncol (2006) 0.85
Increased cell growth due to a new lipase-GEF (Phospholipase D2) fastly acting on Ras. Cell Signal (2012) 0.85
Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 signaling pathways and cell migration by hexachlorobenzene in MDA-MB-231 human breast cancer cell line. Toxicol Sci (2010) 0.85
Electrochemical immunosensor of platelet-derived growth factor with aptamer-primed polymerase amplification. Anal Biochem (2008) 0.85
Antimalarial 4-phenylcoumarins from the stem bark of Hintonia latiflora. J Nat Prod (2006) 0.85
Short-hairpin RNA-mediated stable silencing of Grb2 impairs cell growth and DNA synthesis. Biochem Biophys Res Commun (2007) 0.84
PLD2 has both enzymatic and cell proliferation-inducing capabilities, that are differentially regulated by phosphorylation and dephosphorylation. Biochem Biophys Res Commun (2009) 0.84
[Expression of BRD7-interacting proteins,BRD2 and BRD3, in nasopharyngeal carcinoma tissues]. Ai Zheng (2003) 0.84
In vitro and in vivo characterization and strain safety of Lactobacillus reuteri NCIMB 30253 for probiotic applications. Can J Microbiol (2012) 0.84
Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst (2004) 0.83
Phospholipase D (PLD) gene expression in human neutrophils and HL-60 differentiation. J Leukoc Biol (2005) 0.83
A non-mitotic role for Aurora kinase A as a direct activator of cell migration upon interaction with PLD, FAK and Src. J Cell Sci (2015) 0.83
Comparative phytochemical analysis of four Mexican Nymphaea species. Phytochemistry (2005) 0.83
Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J Immunother (2010) 0.82